Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
AD PHARMA from Châtelet, company number BE0736833279, closed financial year 2025 with a result of € 88,132 after tax. For that financial year AD PHARMA recorded a gross margin of € 147,498 and equity of € 118,742. Compared with financial year 2024, the result moved from € 28,775 to € 88,132. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 118,742
▲ 288% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 88,132
▲ 206% vs 2024
Profit after tax over the fiscal year.
€ 41,413
▲ 11% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 88,742.
Debts at end 2025
€ 1.1 million
▲ € 1 million vs 2024
€ 101,059 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 728
▼ 82% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 31,522
▲ € 23,768 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 3,097 | € 54,742 | € 46,957 | € 147,498 | ▲ 214% |
| Profit after taxes | € 62,439 | € 35,332 | € 28,775 | € 88,132 | ▲ 206% |
| Equity | € 30,502 | € 30,835 | € 30,609 | € 118,742 | ▲ 288% |
| Total debts | € 239,999 | € 256,286 | € 228,685 | € 1,254,170 | ▲ € 1 million |
| Cash | € 14,983 | € 109,538 | € 37,282 | € 41,413 | ▲ 11% |
| Retained profit | € 502 | € 835 | € 609 | € 88,742 | ▲ € 88,132 |
| Dividend | € 57,000 | € 35,000 | € 29,000 | € 0 | ▼ 100% |
| Bank debt | € 175,998 | € 151,420 | € 126,555 | € 1,132,497 | ▲ € 1 million |
| Balance sheet total | € 270,502 | € 287,121 | € 259,294 | € 1,372,911 | ▲ € 1.1 million |
Key figures of AD PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AD PHARMA?
What happened at AD PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 88,132 (▲ 206% vs 2024). Source: NBB ↗
- Christophe Dimitri became a director. NBB
- New establishment in Châtelet. KBO
- Start of the company according to the CBE. KBO
In short
From € 62,439 profit in 2022 to € 88,132 profit in 2025.
Paid € 42,499 in corporate taxes since 2022.
Best year ever: 2025, with € 88,132 profit.
Paid out € 121,000 in dividends to the owners in total.
Management
Behind AD PHARMA is Christophe Dimitri. It owns 100% of Pharmacie Andenelle and 100% of Pharmacie du Perron itself.
Directors
According to the 2025 annual accounts
since 2019
Establishments
Establishment units
Physical locations of this company
Rue de la Pauche 13
6200 Châtelet
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0736.833.279
- VAT number
- BE 0736.833.279
- Registered office
- Rue de la Pauche 13, 6200 Châtelet
- Names & denominations
- AD PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2019
- Peppol
- Active · Active since 11 Jul 2025
- Activities · NACE
Detailhandel in farmaceutische producten